Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

Weight loss drugs like Wegovy and Zepbound are getting cheaper, if you are willing to pay out of pocket for the medications.

Wegovy and Zepbound, which both sell for a list ... Aronne serves as a chief medical adviser for Veru, a company developing an experimental weight loss drug, and was the principal investigator ...

Veru Inc (VERU) reports positive Phase 2B study ... significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

Veru's enobosarm shows safety when combined with Wegovy, Advanz-Alvotech expand biosimilar deal, Keros gets Glass Lewis support, and GeNeuro receives debt moratorium.